Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 436
Filtrer
1.
Cells ; 13(12)2024 Jun 17.
Article de Anglais | MEDLINE | ID: mdl-38920671

RÉSUMÉ

(1) Background: The effects of short-term social isolation during adulthood have not yet been fully established in rats behaviourally, and not at all transcriptomically in the medial prefrontal cortex (mPFC). (2) Methods: We measured the behavioural effects of housing adult male rats in pairs or alone for 10 days. We also used RNA sequencing to measure the accompanying gene expression alterations in the mPFC of male rats. (3) Results: The isolated animals exhibited reduced sociability and social novelty preference, but increased social interaction. There was no change in their aggression, anxiety, or depression-like activity. Transcriptomic analysis revealed a differential expression of 46 genes between the groups. The KEGG pathway analysis showed that differentially expressed genes are involved in neuroactive ligand-receptor interactions, particularly in the dopaminergic and peptidergic systems, and addiction. Subsequent validation confirmed the decreased level of three altered genes: regulator of G protein signalling 9 (Rgs9), serotonin receptor 2c (Htr2c), and Prodynorphin (Pdyn), which are involved in dopaminergic, serotonergic, and peptidergic function, respectively. Antagonizing Htr2c confirmed its role in social novelty discrimination. (4) Conclusions: Social homeostatic regulations include monoaminergic and peptidergic systems of the mPFC.


Sujet(s)
Cortex préfrontal , Transduction du signal , Isolement social , Animaux , Cortex préfrontal/métabolisme , Mâle , Rats , Monoamines biogènes/métabolisme , Rat Sprague-Dawley , Comportement animal , Récepteur de la sérotonine de type 5-HT2C/métabolisme , Récepteur de la sérotonine de type 5-HT2C/génétique , Enképhalines/métabolisme , Enképhalines/génétique , Précurseurs de protéines/métabolisme , Précurseurs de protéines/génétique , Transcriptome/génétique , Régulation de l'expression des gènes
2.
Sci Adv ; 10(26): eadl2675, 2024 Jun 28.
Article de Anglais | MEDLINE | ID: mdl-38941473

RÉSUMÉ

Declined memory is a hallmark of Alzheimer's disease (AD). Experiments in rodents and human postmortem studies suggest that serotonin (5-hydroxytryptamine, 5-HT) plays a role in memory, but the underlying mechanisms are unknown. Here, we investigate the role of 5-HT 2C receptor (5-HT2CR) in regulating memory. Transgenic mice expressing a humanized HTR2C mutation exhibit impaired plasticity of hippocampal ventral CA1 (vCA1) neurons and reduced memory. Further, 5-HT neurons project to and synapse onto vCA1 neurons. Disruption of 5-HT synthesis in vCA1-projecting neurons or deletion of 5-HT2CRs in the vCA1 impairs neural plasticity and memory. We show that a selective 5-HT2CR agonist, lorcaserin, improves synaptic plasticity and memory in an AD mouse model. Cumulatively, we demonstrate that hippocampal 5-HT2CR signaling regulates memory, which may inform the use of 5-HT2CR agonists in the treatment of dementia.


Sujet(s)
Maladie d'Alzheimer , Mémoire , Souris transgéniques , Plasticité neuronale , Récepteur de la sérotonine de type 5-HT2C , Animaux , Humains , Récepteur de la sérotonine de type 5-HT2C/métabolisme , Récepteur de la sérotonine de type 5-HT2C/génétique , Mémoire/effets des médicaments et des substances chimiques , Mémoire/physiologie , Souris , Plasticité neuronale/effets des médicaments et des substances chimiques , Maladie d'Alzheimer/métabolisme , Hippocampe/métabolisme , Hippocampe/effets des médicaments et des substances chimiques , Sérotonine/métabolisme , Modèles animaux de maladie humaine , Région CA1 de l'hippocampe/métabolisme , Région CA1 de l'hippocampe/effets des médicaments et des substances chimiques , Neurones/métabolisme , Neurones/effets des médicaments et des substances chimiques , Agonistes des récepteurs 5-HT2 de la sérotonine/pharmacologie
3.
Epilepsia ; 65(7): e125-e130, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38738911

RÉSUMÉ

Because of its involvement in breathing control and neuronal excitability, dysregulation of the serotonin (5-HT) 2C receptor (5-HT2C) might play a key role in sudden unexpected death in epilepsy. Seizure-induced respiratory arrest is thus prevented by a 5-HT2B/C agonist in different seizure model. However, the specific contribution of 5-HT2C in chronic epilepsy-related respiratory dysfunction remains unknown. In a rat model of temporal lobe epilepsy (EPI rats), in which we previously reported interictal respiratory dysfunctions and a reduction of brainstem 5-HT tone, quantitative reverse transcriptase polymerase chain reaction showed overexpression of TPH2 (5-HT synthesis enzyme), SERT (5-HT reuptake transporter), and 5-HT2C transcript levels in the brainstem of EPI rats, and of RNA-specific adenosine deaminase (ADAR1, ADAR2) involved in the production of 5-HT2C isoforms. Interictal ventilation was assessed with whole-body plethysmography before and 2 h after administration of SB242084 (2 mg/kg), a specific antagonist of 5-HT2C. As expected, SB242084 administration induced a progressive decrease in ventilatory parameters and an alteration of breathing stability in both control and EPI rats. However, the size of the SB242084 effect was lower in EPI rats than in controls. Increased 5-HT2C gene expression in the brainstem of EPI rats could be part of a compensatory mechanism against epilepsy-related low 5-HT tone and expression of 5-HT2C isoforms for which 5-HT affinity might be lower.


Sujet(s)
Tronc cérébral , Modèles animaux de maladie humaine , Épilepsie temporale , Récepteur de la sérotonine de type 5-HT2C , Animaux , Récepteur de la sérotonine de type 5-HT2C/génétique , Récepteur de la sérotonine de type 5-HT2C/métabolisme , Rats , Épilepsie temporale/physiopathologie , Épilepsie temporale/métabolisme , Tronc cérébral/métabolisme , Tronc cérébral/effets des médicaments et des substances chimiques , Mâle , Tryptophane 5-monooxygenase/génétique , Tryptophane 5-monooxygenase/métabolisme , Transporteurs de la sérotonine/génétique , Transporteurs de la sérotonine/métabolisme , Indoles/pharmacologie , Adenosine deaminase/génétique , Adenosine deaminase/métabolisme , Rat Sprague-Dawley , Antagonistes des récepteurs 5-HT2 de la sérotonine/pharmacologie , Aminopyridines , Thiophènes
4.
Endocrinology ; 165(7)2024 May 27.
Article de Anglais | MEDLINE | ID: mdl-38815086

RÉSUMÉ

The serotonin 2C receptor (5-HT2CR)-melanocortin pathway plays well-established roles in the regulation of feeding behavior and body weight homeostasis. Dysfunctions in this system, such as loss-of-function mutations in the Htr2c gene, can lead to hyperphagia and obesity. In this study, we aimed to investigate the potential therapeutic strategies for ameliorating hyperphagia, hyperglycemia, and obesity associated with a loss-of-function mutation in the Htr2c gene (Htr2cF327L/Y). We demonstrated that reexpressing functional 5-HT2CR solely in hypothalamic pro-opiomelanocortin (POMC) neurons is sufficient to reduce food intake and body weight in Htr2cF327L/Y mice subjected to a high-fat diet (HFD). In addition, 5-HT2CR expression restores the responsiveness of POMC neurons to lorcaserin, a selective agonist for 5-HT2CR. Similarly, administration of melanotan II, an agonist of the melanocortin receptor 4 (MC4R), effectively suppresses feeding and weight gain in Htr2cF327L/Y mice. Strikingly, promoting wheel-running activity in Htr2cF327L/Y mice results in a decrease in HFD consumption and improved glucose homeostasis. Together, our findings underscore the crucial role of the melanocortin system in alleviating hyperphagia and obesity related to dysfunctions of the 5-HT2CR, and further suggest that MC4R agonists and lifestyle interventions might hold promise in counteracting hyperphagia, hyperglycemia, and obesity in individuals carrying rare variants of the Htr2c gene.


Sujet(s)
Alimentation riche en graisse , Hyperphagie , Obésité , Pro-opiomélanocortine , Récepteur de la mélanocortine de type 4 , Récepteur de la sérotonine de type 5-HT2C , Animaux , Récepteur de la sérotonine de type 5-HT2C/métabolisme , Récepteur de la sérotonine de type 5-HT2C/génétique , Mâle , Souris , Hyperphagie/métabolisme , Hyperphagie/génétique , Pro-opiomélanocortine/métabolisme , Pro-opiomélanocortine/génétique , Obésité/métabolisme , Obésité/génétique , Récepteur de la mélanocortine de type 4/génétique , Récepteur de la mélanocortine de type 4/métabolisme , Récepteur de la mélanocortine de type 4/agonistes , Hormone mélanotrope alpha/pharmacologie , Hormone mélanotrope alpha/analogues et dérivés , Mutation perte de fonction , Hypothalamus/métabolisme , Poids/effets des médicaments et des substances chimiques , Consommation alimentaire/effets des médicaments et des substances chimiques , Consommation alimentaire/physiologie , Consommation alimentaire/génétique , Neurones/métabolisme , Neurones/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Hyperglycémie/métabolisme , Hyperglycémie/génétique , Souris de lignée C57BL , Benzazépines , Peptides cycliques
5.
Biomed Pharmacother ; 175: 116739, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38759288

RÉSUMÉ

BACKGROUND: Ketamine, as a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, was originally used in general anesthesia. Epidemiological data show that ketamine has become one of the most commonly abused drugs in China. Ketamine administration might cause cognitive impairment; however, its molecular mechanism remains unclear. The glymphatic system is a lymphoid system that plays a key role in metabolic waste removal and cognitive regulation in the central nervous system. METHODS: Focusing on the glymphatic system, this study evaluated the behavioral performance and circulatory function of the glymphatic system by building a short-term ketamine administration model in mice, and detected the expression levels of the 5-HT2c receptor, ΔFosb, Pten, Akt, and Aqp4 in the hippocampus. Primary astrocytes were cultured to verify the regulatory relationships among related indexes using a 5-HT2c receptor antagonist, a 5-HT2c receptor short interfering RNA (siRNA), and a ΔFosb siRNA. RESULTS: Ketamine administration induced ΔFosb accumulation by increasing 5-HT2c receptor expression in mouse hippocampal astrocytes and primary astrocytes. ΔFosb acted as a transcription factor to recognize the AATGATTAAT bases in the 5' regulatory region of the Aqp4 gene (-1096 bp to -1087 bp), which inhibited Aqp4 expression, thus causing the circulatory dysfunction of the glymphatic system, leading to cognitive impairment. CONCLUSIONS: Although this regulatory mechanism does not involve the Pten/Akt pathway, this study revealed a new mechanism of ketamine-induced cognitive impairment in non-neuronal systems, and provided a theoretical basis for the safety of clinical treatment and the effectiveness of withdrawal.


Sujet(s)
Astrocytes , Dysfonctionnement cognitif , Système glymphatique , Hippocampe , Kétamine , Animaux , Kétamine/pharmacologie , Kétamine/toxicité , Astrocytes/effets des médicaments et des substances chimiques , Astrocytes/métabolisme , Dysfonctionnement cognitif/induit chimiquement , Dysfonctionnement cognitif/métabolisme , Souris , Mâle , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Système glymphatique/effets des médicaments et des substances chimiques , Système glymphatique/métabolisme , Protéines proto-oncogènes c-akt/métabolisme , Aquaporine-4/métabolisme , Aquaporine-4/génétique , Récepteur de la sérotonine de type 5-HT2C/métabolisme , Récepteur de la sérotonine de type 5-HT2C/génétique , Souris de lignée C57BL , Cellules cultivées , Protéines proto-oncogènes c-fos/métabolisme , Protéines proto-oncogènes c-fos/génétique , Phosphohydrolase PTEN/métabolisme , Phosphohydrolase PTEN/génétique
6.
Eat Weight Disord ; 29(1): 31, 2024 Apr 26.
Article de Anglais | MEDLINE | ID: mdl-38668826

RÉSUMÉ

PURPOSE: Several studies have investigated the association between anorexia nervosa and polymorphisms of genes regulating serotonin neurotransmission, with a focus on the rs6311 polymorphism of 5-HTR2A. However, inconsistent results of these studies and conflicting conclusions of existing meta-analyses complicate the understanding of a possible association. We have updated these results and evaluated the involvement of other serotonin receptor gene polymorphisms in anorexia nervosa. METHODS: Adhering to PRISMA guidelines, we have searched studies on anorexia nervosa and serotonin-regulating genes published from 1997 to 2022, selected those concerning receptor genes and meta-analyzed the results from twenty candidate gene studies on the 5-HTR2A rs6311 polymorphism and the 5-HTR2C rs6318 polymorphism. RESULTS: Present analyses reveal an association for the 5-HTR2A rs6311 polymorphism, with G and A alleles, across eighteen studies (2049 patients, 2877 controls; A vs. G allele, Odds Ratio = 1.24; 95% Confidence Interval = 1.06-1.47; p = 0.009). However, after geographic subgrouping, an association emerged only in a Southern European area, involving five studies (722 patients, 773 controls; A vs. G allele, Odds Ratio = 1.82; 95% Confidence Interval = 1.41-2.37; p < 0.00001). No association was observed for the 5-HTR2C rs6318 polymorphism across three studies. CONCLUSIONS: To date, the involvement in the pathophysiology of anorexia nervosa of the 5-HTR2A rs6311 polymorphism appears limited to a specific genetic and/or environmental context, while that of the 5-HTR2C rs6318 polymorphism seems excluded. Genome-wide association studies and epigenetic studies will likely offer deeper insights of genetic and environmental factors possibly contributing to the disorder. LEVEL OF EVIDENCE: III Evidence obtained from well-designed cohort or case-control analytic studies. Clinical trial registration PROSPERO registration number: CRD42021246122.


Sujet(s)
Anorexie mentale , Polymorphisme de nucléotide simple , Récepteur de la sérotonine de type 5-HT2A , Récepteur de la sérotonine de type 5-HT2C , Humains , Anorexie mentale/génétique , Prédisposition génétique à une maladie/génétique , Récepteur de la sérotonine de type 5-HT2A/génétique , Récepteur de la sérotonine de type 5-HT2C/génétique
7.
Pharmacol Rep ; 75(6): 1502-1521, 2023 Dec.
Article de Anglais | MEDLINE | ID: mdl-37923824

RÉSUMÉ

BACKGROUND: Serotonin (5-HT) 5-HT2C receptor mRNA editing (at five sites, A-E), implicated in neuropsychiatric disorders, including clinical depression, remains unexplored during alcohol abstinence-often accompanied by depressive symptoms. METHODS: We used deep sequencing to investigate 5-HT2C receptor editing in mice during early ethanol deprivation following prolonged alcohol exposure and mice lacking tryptophan hydroxylase (TPH)2, a key enzyme in central 5-HT production. We also examined Tph2 expression in ethanol-deprived animals using quantitative real-time PCR (qPCR). RESULTS: Cessation from chronic 10% ethanol exposure in a two-bottle choice paradigm enhanced immobility time and decreased latency in the forced swim test (FST), indicating a depression-like phenotype. In the hippocampus, ethanol-deprived "high ethanol-drinking" mice displayed reduced Tph2 expression, elevated 5-HT2C receptor editing efficiency, and decreased frequency of the D mRNA variant, encoding the less-edited INV protein isoform. Tph2-/- mice showed attenuated receptor editing in the hippocampus and elevated frequency of non-edited None and D variants. In the prefrontal cortex, Tph2 deficiency increased receptor mRNA editing at site D and reduced the frequency of AB transcript, predicting a reduction in the corresponding partially edited VNI isoform. CONCLUSIONS: Our findings reveal differential effects of 5-HT depletion and ethanol cessation on 5-HT2C receptor editing. Central 5-HT depletion attenuated editing in the prefrontal cortex and the hippocampus, whereas ethanol deprivation, coinciding with reduced Tph2 expression in the hippocampus, enhanced receptor editing efficiency specifically in this brain region. This study highlights the interplay between 5-HT synthesis, ethanol cessation, and 5-HT2C receptor editing, providing potential mechanism underlying increased ethanol consumption and deprivation.


Sujet(s)
Récepteur de la sérotonine de type 5-HT2C , Sérotonine , Souris , Animaux , Sérotonine/métabolisme , Récepteur de la sérotonine de type 5-HT2C/génétique , Récepteur de la sérotonine de type 5-HT2C/métabolisme , Éthanol , Encéphale/métabolisme , ARN messager/génétique
8.
Bull Exp Biol Med ; 175(4): 424-426, 2023 Aug.
Article de Anglais | MEDLINE | ID: mdl-37768455

RÉSUMÉ

Molecular genetic analysis of polymorphic variants of serotonin receptor genes (HTR2C and HTR2A) was performed in 89 healthy medical students and regulatory and adaptive capacities were determined by cardiorespiratory synchronism. The relationship of serotonin receptor gene polymorphisms and the regulatory and adaptive capabilities of the body were revealed. The highly active *G allele and *G/*G genotype of the serotonin receptor HTR2C gene and the heterozygous *A/*G genotype of the serotonin receptor HTR2A gene are associated with "good" regulatory and adaptive capacities. The low-active *C allele of the serotonin receptor HTR2C gene is associated with "low" regulatory and adaptive capacities.


Sujet(s)
Étudiant médecine , Humains , Polymorphisme génétique/génétique , Génotype , Récepteurs sérotoninergiques , Allèles , Récepteur de la sérotonine de type 5-HT2A/génétique , Polymorphisme de nucléotide simple/génétique , Récepteur de la sérotonine de type 5-HT2C/génétique
9.
Biomolecules ; 13(5)2023 05 08.
Article de Anglais | MEDLINE | ID: mdl-37238670

RÉSUMÉ

The complex role of the serotonin system in respiratory function and inflammatory diseases such as asthma is unclear. Our study investigated platelet serotonin (5-HT) levels and platelet monoamine oxidase B (MAO-B) activity, as well as associations with HTR2A (rs6314; rs6313), HTR2C (rs3813929; rs518147), and MAOB (rs1799836; rs6651806) gene polymorphisms in 120 healthy individuals and 120 asthma patients of different severity and phenotypes. Platelet 5-HT concentration was significantly lower, while platelet MAO-B activity was considerably higher in asthma patients; however, they did not differ between patients with different asthma severity or phenotypes. Only the healthy subjects, but not the asthma patients, carrying the MAOB rs1799836 TT genotype had significantly lower platelet MAO-B activity than the C allele carriers. No significant differences in the frequency of the genotypes, alleles, or haplotypes for any of the investigated HTR2A, HTR2C and MAOB gene polymorphisms have been observed between asthma patients and healthy subjects or between patients with various asthma phenotypes. However, the carriers of the HTR2C rs518147 CC genotype or C allele were significantly less frequent in severe asthma patients than in the G allele carriers. Further studies are necessary to elucidate the involvement of the serotonergic system in asthma pathophysiology.


Sujet(s)
Asthme , Monoamine oxidase , Récepteur de la sérotonine de type 5-HT2A , Récepteur de la sérotonine de type 5-HT2C , Allèles , Génotype , Monoamine oxidase/génétique , Polymorphisme génétique , Sérotonine , Humains , Récepteur de la sérotonine de type 5-HT2A/génétique , Récepteur de la sérotonine de type 5-HT2C/génétique , Asthme/génétique
11.
Nihon Yakurigaku Zasshi ; 158(1): 43-46, 2023.
Article de Japonais | MEDLINE | ID: mdl-36596489

RÉSUMÉ

Post-traumatic stress disorder (PTSD) is often treated by (1) selective serotonin reuptake inhibitors (SSRIs), (2) exposure therapy, or a combination of the two. However, while all treatments have some efficacy, they are not fully effective. It is necessary to elucidate the causes of inadequate efficacy and to direct the development of effective treatments. First, regarding (1), pharmacological studies have indicated that the 5-HT2C receptor is one of the receptor subtypes that interfere with the therapeutic effects of SSRIs. To compensate for nonselective effects in pharmacological manipulations, we replicated pharmacological results using mice deficient in the 5-HT2C receptor gene. However, since either pharmacological blockade or gene knockout of the 5-HT2C receptor could increase locomotor activity, the locomotor-enhancing effects make the interpretations of results difficult. Therefore, we used the conditioned lick suppression test to evaluate fear response using corrected values that consider the effects of differences in locomotor activity, thereby eliminating this possibility. Next, to address (2), we conducted fear conditioning by simultaneously presenting a composite of sound and environmental stimuli and then re-exposing the subjects to the sound and environmental stimuli separately. We found that the fear response to the sound stimuli quickly decreased, while the fear response to the environmental stimuli did not diminish even after repeated exposure. Thus, exposure therapy may exacerbate PTSD, depending on the method used. In this paper, we will introduce the above results and suggest directions for future PTSD research.


Sujet(s)
Troubles de stress post-traumatique , Souris , Animaux , Troubles de stress post-traumatique/traitement médicamenteux , Inbiteurs sélectifs de la recapture de la sérotonine/pharmacologie , Sérotonine , Récepteur de la sérotonine de type 5-HT2C/génétique , Conditionnement classique/physiologie
12.
Nat Med ; 28(12): 2537-2546, 2022 12.
Article de Anglais | MEDLINE | ID: mdl-36536256

RÉSUMÉ

Serotonin reuptake inhibitors and receptor agonists are used to treat obesity, anxiety and depression. Here we studied the role of the serotonin 2C receptor (5-HT2CR) in weight regulation and behavior. Using exome sequencing of 2,548 people with severe obesity and 1,117 control individuals without obesity, we identified 13 rare variants in the gene encoding 5-HT2CR (HTR2C) in 19 unrelated people (3 males and 16 females). Eleven variants caused a loss of function in HEK293 cells. All people who carried variants had hyperphagia and some degree of maladaptive behavior. Knock-in male mice harboring a human loss-of-function HTR2C variant developed obesity and reduced social exploratory behavior; female mice heterozygous for the same variant showed similar deficits with reduced severity. Using the 5-HT2CR agonist lorcaserin, we found that depolarization of appetite-suppressing proopiomelanocortin neurons was impaired in knock-in mice. In conclusion, we demonstrate that 5-HT2CR is involved in the regulation of human appetite, weight and behavior. Our findings suggest that melanocortin receptor agonists might be effective in treating severe obesity in individuals carrying HTR2C variants. We suggest that HTR2C should be included in diagnostic gene panels for severe childhood-onset obesity.


Sujet(s)
Obésité morbide , Récepteur de la sérotonine de type 5-HT2C , Animaux , Enfant , Femelle , Humains , Mâle , Souris , Cellules HEK293 , Obésité/génétique , Récepteur de la sérotonine de type 5-HT2C/génétique , Sérotonine , Agonistes des récepteurs 5-HT2 de la sérotonine/pharmacologie , Adaptation psychologique
13.
Transl Psychiatry ; 12(1): 487, 2022 11 19.
Article de Anglais | MEDLINE | ID: mdl-36402746

RÉSUMÉ

Serotonin 2C receptors (5-HT2CRs) are widely distributed throughout the brain and are strongly implicated in the pathophysiology of anxiety disorders such as post-traumatic stress disorder (PTSD). Although in recent years, a considerable amount of evidence supports 5-HT2CRs facilitating effect on anxiety behavior, the involvement in learned fear responses and fear extinction is rather unexplored. Here, we used a 5-HT2CR knock-out mouse line (2CKO) to gain new insights into the involvement of 5-HT2CRs in the neuronal fear circuitry. Using a cued fear conditioning paradigm, our results revealed that global loss of 5-HT2CRs exclusively accelerates fear extinction, without affecting fear acquisition and fear expression. To investigate the neuronal substrates underlying the extinction enhancing effect, we mapped the immediate-early gene product cFos, a marker for neuronal activity, in the dorsal raphe nucleus (DRN), amygdala and bed nucleus of the stria terminalis (BNST). Surprisingly, besides extinction-associated changes, our results revealed alterations in neuronal activity even under basal home cage conditions in specific subregions of the DRN and the BNST in 2CKO mice. Neuronal activity in the dorsal BNST was shifted in an extinction-supporting direction due to 5-HT2CR knock-out. Finally, the assessment of DRN-BNST connectivity using antero- and retrograde tracing techniques uncovered a discrete serotonergic pathway projecting from the most caudal subregion of the DRN (DRC) to the anterodorsal portion of the BNST (BNSTad). This serotonergic DRC-BNSTad pathway showed increased neuronal activity in 2CKO mice. Thus, our results provide new insights for the fear extinction network by revealing a specific serotonergic DRC-BNSTad pathway underlying a 5-HT2CR-sensitive mechanism with high significance in the treatment of PTSD.


Sujet(s)
Peur , Noyaux du septum , Souris , Animaux , Peur/physiologie , Noyaux du septum/métabolisme , Noyau dorsal du raphé/métabolisme , Extinction (psychologie) , Récepteur de la sérotonine de type 5-HT2C/génétique , Récepteur de la sérotonine de type 5-HT2C/métabolisme
14.
Rev. int. androl. (Internet) ; 20(4): 217-224, oct.-dic. 2022. tab
Article de Anglais | IBECS | ID: ibc-210760

RÉSUMÉ

Introduction and objectives: Premature ejaculation (PE) is characterized by shorter intravaginal ejaculation latency time than it is acceptable for the patient or partner. It is thought that lifelong PE is a neurobiological dysfunction associated with genetic predisposition and with central serotonin neurotransmission dysfunction in receptors. To contribute to the understanding the genetic etiology of lifelong PE, it was planned to compare the 5-HT2C receptor gene rs3813929, rs518147, 5-HT1A receptor gene rs6295, 5-HT1B receptor gene rs11568817 of lifelong PE patients to healthy controls. Materials and methods: For this purpose, 100 patients with premature ejaculation and 100 healthy controls were included in the study. Blood samples for DNA extraction were obtained. Appropriate procedures were applied to the probes (rs3813929, rs518147, rs6295, rs11568817) suitable for the DNA studied. Results: A statistically significant relationship was found between the rs11568817 polymorphism (p=0.019) in the 5-HT1B receptor gene and the rs518147 polymorphism (p=0.016) in the 5-HT2C receptor gene. Also, no statistically significant relationship was found between 5-HT1A receptor gene rs6295 polymorphism and 5-HT2C receptor gene rs3813929 polymorphism and lifelong PE. Conclusions: The relationship between rs3813929 and rs11568817 polymorphisms with lifelong PE was confirmed. Repeating the study in larger sample groups could be useful in determining the genetic etiology of PE. (AU)


Introducción y objetivos: La eyaculación precoz (EP) se caracteriza por un tiempo de latencia de eyaculación intravaginal más corto de lo que es aceptable para el paciente o para la pareja. Se cree que la EP de por vida es una disfunción neurobiológica asociada con la predisposición genética y con la disfunción central de la neurotransmisión de serotonina en los receptores. Para contribuir a la comprensión de la etiología genética de la EP de por vida, se planificó comparar el gen del receptor 5-HT2C rs3813929, rs518147, el gen del receptor 5-HT1A rs6295 y el gen del receptor 5-HT1B rs11568817 de pacientes con EP de por vida con controles sanos. Materiales y métodos: Para este propósito, se incluyeron en el estudio 100 pacientes con eyaculación precoz y 100 controles sanos. Se obtuvieron muestras de sangre para extracción de ADN. Se aplicaron procedimientos apropiados a las sondas (rs3813929, rs518147, rs6295, rs11568817) adecuadas para el ADN estudiado. Resultados: Se encontró una relación estadísticamente significativa entre el polimorfismo rs11568817 (p=0,019) en el gen del receptor 5-HT1B y el polimorfismo rs518147 (p=0,016) en el gen del receptor 5-HT2C. Además, no se encontró una relación estadísticamente significativa entre el polimorfismo del gen del receptor 5-HT1A rs6295 y el polimorfismo del gen del receptor 5-HT2C rs3813929 y la EP de por vida. Conclusiones: Se confirmó la relación entre los polimorfismos rs3813929 y rs11568817 con EP de por vida. Repetir el estudio en grupos de muestra más grandes podría ser útil para determinar la etiología genética de la EP. (AU)


Sujet(s)
Humains , Mâle , Jeune adulte , Adulte , Adulte d'âge moyen , Éjaculation précoce/étiologie , Polymorphisme génétique , Sérotonine , Récepteur de la sérotonine de type 5-HT1A/génétique , Récepteur de la sérotonine de type 5-HT1B/génétique , Récepteur de la sérotonine de type 5-HT2C/génétique
15.
Rev Int Androl ; 20(4): 217-224, 2022.
Article de Anglais | MEDLINE | ID: mdl-35906129

RÉSUMÉ

INTRODUCTION AND OBJECTIVES: Premature ejaculation (PE) is characterized by shorter intravaginal ejaculation latency time than it is acceptable for the patient or partner. It is thought that lifelong PE is a neurobiological dysfunction associated with genetic predisposition and with central serotonin neurotransmission dysfunction in receptors. To contribute to the understanding the genetic etiology of lifelong PE, it was planned to compare the 5-HT2C receptor gene rs3813929, rs518147, 5-HT1A receptor gene rs6295, 5-HT1B receptor gene rs11568817 of lifelong PE patients to healthy controls. MATERIALS AND METHODS: For this purpose, 100 patients with premature ejaculation and 100 healthy controls were included in the study. Blood samples for DNA extraction were obtained. Appropriate procedures were applied to the probes (rs3813929, rs518147, rs6295, rs11568817) suitable for the DNA studied. RESULTS: A statistically significant relationship was found between the rs11568817 polymorphism (p=0.019) in the 5-HT1B receptor gene and the rs518147 polymorphism (p=0.016) in the 5-HT2C receptor gene. Also, no statistically significant relationship was found between 5-HT1A receptor gene rs6295 polymorphism and 5-HT2C receptor gene rs3813929 polymorphism and lifelong PE. CONCLUSIONS: The relationship between rs3813929 and rs11568817 polymorphisms with lifelong PE was confirmed. Repeating the study in larger sample groups could be useful in determining the genetic etiology of PE.


Sujet(s)
Éjaculation précoce , Humains , Mâle , Polymorphisme de nucléotide simple , Éjaculation précoce/étiologie , Récepteur de la sérotonine de type 5-HT1A/génétique , Récepteur de la sérotonine de type 5-HT1B/génétique , Récepteur de la sérotonine de type 5-HT2C/génétique , Sérotonine
16.
Transl Psychiatry ; 12(1): 58, 2022 02 11.
Article de Anglais | MEDLINE | ID: mdl-35145065

RÉSUMÉ

Previous findings have proposed that drugs targeting 5-HT2C receptors could be promising candidates in the treatment of trauma- and stress-related disorders. However, the reduction of conditioned freezing observed in 5-HT2C receptor knock-out (KO) mice in previous studies could alternatively be accounted for by increased locomotor activity. To neutralize the confound of individual differences in locomotor activity, we measured a ratio of fear responses during versus before the presentation of a conditioned stimulus previously paired with a footshock (as a fear measure) by utilizing a conditioned licking suppression paradigm. We first confirmed that 5-HT2C receptor gene KO attenuated fear responses to distinct types of single conditioned stimuli (context or tone) independently of locomotor activity. We then assessed the effects of 5-HT2C receptor gene KO on compound fear responses by examining mice that were jointly conditioned to a context and a tone and later re-exposed separately to each. We found that separate re-exposure to individual components of a complex fear memory (i.e., context and tone) failed to elicit contextual fear extinction in both 5-HT2C receptor gene KO and wild-type mice, and also abolished differences between genotypes in tone-cued fear extinction. This study delineates a previously overlooked role of 5-HT2C receptors in conditioned fear responses, and invites caution in the future assessment of molecular targets and candidate therapies for the treatment of PTSD.


Sujet(s)
Signaux , Peur , Récepteur de la sérotonine de type 5-HT2C/métabolisme , Animaux , Extinction (psychologie)/physiologie , Peur/physiologie , Souris , Souris knockout , Récepteur de la sérotonine de type 5-HT2C/génétique , Sérotonine
17.
Elife ; 102021 12 17.
Article de Anglais | MEDLINE | ID: mdl-34919051

RÉSUMÉ

Metastasis is responsible for approximately 90% of cancer-associated mortality but few models exist that allow for rapid and effective screening of anti-metastasis drugs. Current mouse models of metastasis are too expensive and time consuming to use for rapid and high-throughput screening. Therefore, we created a unique screening concept utilizing conserved mechanisms between zebrafish gastrulation and cancer metastasis for identification of potential anti-metastatic drugs. We hypothesized that small chemicals that interrupt zebrafish gastrulation might also suppress metastatic progression of cancer cells and developed a phenotype-based chemical screen to test the hypothesis. The screen used epiboly, the first morphogenetic movement in gastrulation, as a marker and enabled 100 chemicals to be tested in 5 hr. The screen tested 1280 FDA-approved drugs and identified pizotifen, an antagonist for serotonin receptor 2C (HTR2C) as an epiboly-interrupting drug. Pharmacological and genetic inhibition of HTR2C suppressed metastatic progression in a mouse model. Blocking HTR2C with pizotifen restored epithelial properties to metastatic cells through inhibition of Wnt signaling. In contrast, HTR2C induced epithelial-to-mesenchymal transition through activation of Wnt signaling and promoted metastatic dissemination of human cancer cells in a zebrafish xenotransplantation model. Taken together, our concept offers a novel platform for discovery of anti-metastasis drugs.


Sujet(s)
Mouvement cellulaire/effets des médicaments et des substances chimiques , Embryon non mammalien/effets des médicaments et des substances chimiques , Transition épithélio-mésenchymateuse , Gastrulation/effets des médicaments et des substances chimiques , Tests de criblage à haut débit/méthodes , Pizotifène/pharmacologie , Récepteur de la sérotonine de type 5-HT2C/génétique , Antagonistes des récepteurs 5-HT2 de la sérotonine/pharmacologie , Animaux , Découverte de médicament , Femelle , Humains , Souris de lignée BALB C , Métastase tumorale/traitement médicamenteux , Métastase tumorale/prévention et contrôle , Transduction du signal/effets des médicaments et des substances chimiques , Bibliothèques de petites molécules/pharmacologie , Transplantation hétérologue , Danio zébré , Protéines de poisson-zèbre/génétique
18.
Zhonghua Nan Ke Xue ; 27(8): 748-752, 2021 Aug.
Article de Chinois | MEDLINE | ID: mdl-34914250

RÉSUMÉ

Premature ejaculation is one of the common male sexual dysfunction diseases. Lifelong premature ejaculation (LPE), characterized by an early onset and a long course of disease, has a variety of negative effects on men. The pathogenesis of LPE has not been clarified, but it is believed to be related to the regulation of 5-HT and the 5-HT1a and 5-HT2c receptors from the perspective of the theory of 5-HT system neurotransmitter disorder. Current studies indicate that the 5-HT transporter gene-linked polymorphic region (5-HTTLPR), 5-HT1a receptor gene polymorphism and 5-HT2c receptor gene polymorphism may be associated with the development of and drug effect on LPE. This article reviews the current studies on the development of LPE, effects of medication and 5-HT system gene polymorphism, and discusses the correlation of 5-HT system gene polymorphism with the development of LPE and effects of medication.


Sujet(s)
Éjaculation précoce , Récepteur de la sérotonine de type 5-HT1A/génétique , Récepteur de la sérotonine de type 5-HT2C/génétique , Transporteurs de la sérotonine/génétique , Sérotonine , Humains , Mâle , Polymorphisme génétique , Éjaculation précoce/génétique , Sérotonine/génétique
19.
Cell Rep ; 37(7): 109997, 2021 11 16.
Article de Anglais | MEDLINE | ID: mdl-34788630

RÉSUMÉ

The anorexigenic effect of serotonergic compounds has largely been attributed to activation of serotonin 2C receptors (Htr2cs). Using mouse genetic models in which Htr2c can be selectively deleted or restored (in Htr2c-null mice), we investigate the role of Htr2c in forebrain Sim1 neurons. Unexpectedly, we find that Htr2c acts in these neurons to promote food intake and counteract the anorectic effect of serotonergic appetite suppressants. Furthermore, Htr2c marks a subset of Sim1 neurons in the paraventricular nucleus of the hypothalamus (PVH). Chemogenetic activation of these neurons in adult mice suppresses hunger, whereas their silencing promotes feeding. In support of an orexigenic role of PVH Htr2c, whole-cell patch-clamp experiments demonstrate that activation of Htr2c inhibits PVH neurons. Intriguingly, this inhibition is due to Gαi/o-dependent activation of ATP-sensitive K+ conductance, a mechanism of action not identified previously in the mammalian nervous system.


Sujet(s)
Sous-unités alpha Gi-Go des protéines G/métabolisme , Noyau paraventriculaire de l'hypothalamus/métabolisme , Récepteur de la sérotonine de type 5-HT2C/métabolisme , Animaux , Anorexie , Anorexigènes/métabolisme , Anorexigènes/pharmacologie , Métabolisme énergétique/physiologie , Comportement alimentaire/physiologie , Faim/physiologie , Hypothalamus/métabolisme , Hypothalamus/physiologie , Mâle , Souris , Souris de souche-129 , Souris de lignée C57BL , Souris knockout , Modèles animaux , Neurones/physiologie , Noyau paraventriculaire de l'hypothalamus/cytologie , Noyau paraventriculaire de l'hypothalamus/physiologie , Potassium/métabolisme , Récepteur de la sérotonine de type 5-HT2C/génétique , Sérotonine/métabolisme , Sérotonine/pharmacologie , Agents sérotoninergiques
20.
J Clin Invest ; 131(24)2021 12 15.
Article de Anglais | MEDLINE | ID: mdl-34673574

RÉSUMÉ

Contrasting with the predicted anorexigenic effect of increasing brain serotonin signaling, long-term use of selective serotonin reuptake inhibitor (SSRI) antidepressants correlates with body weight (BW) gain. This adverse outcome increases the risk of transitioning to obesity and interferes with treatment compliance. Here, we show that orally administered fluoxetine (Flx), a widely prescribed SSRI, increased BW by enhancing food intake in healthy mice at 2 different time points and through 2 distinct mechanisms. Within hours, Flx decreased the activity of a subset of brainstem serotonergic neurons by triggering autoinhibitory signaling through 5-hydroxytryptamine receptor 1a (Htr1a). Following a longer treatment period, Flx blunted 5-hydroxytryptamine receptor 2c (Htr2c) expression and signaling, decreased the phosphorylation of cAMP response element-binding protein (CREB) and STAT3, and dampened the production of pro-opiomelanocortin (POMC, the precursor of α-melanocyte stimulating hormone [α-MSH]) in hypothalamic neurons, thereby increasing food intake. Accordingly, exogenous stimulation of the melanocortin 4 receptor (Mc4r) by cotreating mice with Flx and lipocalin 2, an anorexigenic hormone signaling through this receptor, normalized feeding and BW. Flx and other SSRIs also inhibited CREB and STAT3 phosphorylation in a human neuronal cell line, suggesting that these noncanonical effects could also occur in individuals treated long term with SSRIs. By defining the molecular basis of long-term SSRI-associated weight gain, we propose a therapeutic strategy to counter this effect.


Sujet(s)
Antidépresseurs/effets indésirables , Fluoxétine/effets indésirables , Récepteur de la mélanocortine de type 4/métabolisme , Prise de poids/effets des médicaments et des substances chimiques , Animaux , Antidépresseurs/pharmacologie , Lignée cellulaire , Fluoxétine/pharmacologie , Humains , Souris , Souris knockout , Pro-opiomélanocortine/génétique , Pro-opiomélanocortine/métabolisme , Récepteur de la mélanocortine de type 4/génétique , Récepteur de la sérotonine de type 5-HT1A/génétique , Récepteur de la sérotonine de type 5-HT1A/métabolisme , Récepteur de la sérotonine de type 5-HT2C/génétique , Récepteur de la sérotonine de type 5-HT2C/métabolisme , Facteurs temps , Prise de poids/génétique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE